Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMASCIS-02 allogeneic adipose-derived mesenchymal stem cells in acute ischemic stroke
2019-001724-35Phase 2Active
- Sponsor
- FIBHULP
- Start
- Jul 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Allogeneic adipose-derived mesenchymal stem cells with Placebo (2 arms). Primary endpoint: Safety of adipose tissue-derived mesenchymal stem cells. Started Jul 2022; status: active.
02
Drugs
CSCC_ASC
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2019-001724-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001724-35.